AI Drug Discovery Startup Noetik Raises $14M to Develop Precision Immunotherapies for Cancer Using Machine Learning
-
Noetik, an AI drug discovery company, raised $14M in seed financing to develop precision immunotherapies for cancer using ML and proprietary human data.
-
Noetik has built a multimodal tissue profiling platform combining self-supervised learning and spatial biology to tackle problems in cancer immunology.
-
The funding will support Noetik's internal data generation, ML model development, team expansion in ML, computational biology, and cancer immunology.
-
Noetik aims to rapidly initiate target and drug discovery by learning from molecular, cellular, and tissue data to discover novel therapeutic targets.
-
Noetik was founded by leaders in ML, computational biology, and cancer immunology to build an interdisciplinary team and develop precision immunotherapies.
![](https://mms.businesswire.com/media/20230907509972/en/1881591/23/Ron_and_Jacob_2_%283%29.jpg)